Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993
Debt
Debt-to-Equity RatioN/A
Current Ratio9.64
Quick Ratio9.64
Price-To-Earnings
Trailing P/E Ratio-6.15
Forward P/E Ratio-5.96
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales433.39
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book4.29
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-64.41%
Return on Assets-42.44%
Miscellaneous
Employees21
Outstanding Shares13,190,000
Market Cap$158.62 million
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings results on Thursday, August, 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.22. View Spring Bank Pharmaceuticals' Earnings History.
When is Spring Bank Pharmaceuticals' next earnings date?
What price target have analysts set for SBPH?
4 brokerages have issued 12-month price objectives for Spring Bank Pharmaceuticals' stock. Their predictions range from $25.00 to $35.00. On average, they expect Spring Bank Pharmaceuticals' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 160.9% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.
What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.
Are investors shorting Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totalling 486,690 shares, a decline of 28.8% from the July 13th total of 683,199 shares. Based on an average trading volume of 23,474 shares, the days-to-cover ratio is presently 20.7 days. Approximately 4.8% of the company's stock are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU), Progenics Pharmaceuticals (PGNX), Dova Pharmaceuticals (DOVA), Eidos Therapeutics (EIDX), Verastem (VSTM), Collegium Pharmaceutical (COLL), Prothena (PRTA), ArQule (ARQL), ChemoCentryx (CCXI), Homology Medicines (FIXX), Insys Therapeutics (INSY) and Evolus (EOLS).
Who are Spring Bank Pharmaceuticals' key executives?
Spring Bank Pharmaceuticals' management team includes the folowing people:
- Mr. Martin J. Driscoll, Pres, CEO & Chairman (Age 59)
- Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 68)
- Dr. Nezam H. Afdhal, Chief Medical Officer (Age 61)
- Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 40)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
Media stories about SBPH stock have been trending positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of 0.28 on Accern's scale. They also gave news articles about the company an impact score of 47.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Spring Bank Pharmaceuticals.
Who are Spring Bank Pharmaceuticals' major shareholders?
Spring Bank Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.66%), Morse Asset Management Inc (1.35%), C WorldWide Group Holding A S (0.70%), Bank of New York Mellon Corp (0.29%), Schwab Charles Investment Management Inc. (0.19%) and Renaissance Technologies LLC (0.12%). Company insiders that own Spring Bank Pharmaceuticals stock include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.
Which institutional investors are buying Spring Bank Pharmaceuticals stock?
SBPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Renaissance Technologies LLC, Morse Asset Management Inc and C WorldWide Group Holding A S. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Insider Buying and Selling for Spring Bank Pharmaceuticals.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $11.50.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $158.62 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 21 workers across the globe.
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
